$VVOS News

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M

Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M

Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate

Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

Vivos Therapeutics Announces Restructuring And Cost Reduction Plan With An Annual Savings Target Of $3.6M From Q4 2026

Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center

Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers

Vivos Therapeutics Announces 212% Rise YoY Over Most Recent Six-Week Period In Its New Obstructive Sleep Apnea Patient Referrals At Its Nevada Sleep & Airway Medicine Centers

Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ...

Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts

Vivos Therapeutics, Inc. Q2 2026 Earnings Call Summary

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript

Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate